Cited 0 times in Scipus Cited Count

Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study

DC Field Value Language
dc.contributor.authorPark, SJ-
dc.contributor.authorKim, J-
dc.contributor.authorKim, HS-
dc.contributor.authorLee, JW-
dc.contributor.authorChang, HK-
dc.contributor.authorLee, KH-
dc.contributor.authorKim, DY-
dc.contributor.authorKim, S-
dc.contributor.authorChang, SJ-
dc.contributor.authorHan, SS-
dc.contributor.authorPark, SY-
dc.contributor.authorShim, SH-
dc.date.accessioned2022-12-07T05:53:21Z-
dc.date.available2022-12-07T05:53:21Z-
dc.date.issued2020-
dc.identifier.issn2005-0380-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23136-
dc.description.abstractOBJECTIVE: To evaluate the effectiveness and safety of the combination of pegylated liposomal doxorubicin with carboplatin (CD) compared with those of carboplatin and paclitaxel (CP) for platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer in a real-world setting in Korea. METHODS: We enrolled relevant patients from 9 institutions. All patients received CD or CP as the second- or third-line chemotherapy in routine clinical practice during 2013-2018. The primary endpoints were progression-free survival (PFS) and toxicity. The secondary endpoint included the objective response rate (ORR). RESULTS: Overall, 432 patients (224 and 208 in the CD and CP groups, respectively) were included. With a median follow-up of 18.9 months, the median PFS was not different between the groups (12.7 vs. 13.6 months; hazard ratio, 1.161; 95% confidence interval, 0.923-1.460; p=0.202). The ORR was 74.6% and 80.1% in the CD and CP group, respectively (p=0.556). Age and surgery at relapse were independent prognostic factors. More patients in the CD group significantly experienced a grade 3 to 4 hematologic toxicity and hand-foot syndrome (13.8% vs. 6.3%), whereas grade 2 or more alopecia (6.2% vs. 36.1%), peripheral neuropathy (4.4% vs. 11.4%), and allergic/hypersensitivity reaction (0.4% vs. 8.5%) developed more often in the CP group. CONCLUSIONS: The safety and effectiveness of chemotherapy with CD in a real-world setting were consistent with the results from a randomized controlled study. The different toxicity profiles between the 2 chemotherapy (CD and CP) regimens should be considered in the clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03562533.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHCarboplatin-
dc.subject.MESHCohort Studies-
dc.subject.MESHDoxorubicin-
dc.subject.MESHFallopian Tube Neoplasms-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOvarian Neoplasms-
dc.subject.MESHPaclitaxel-
dc.subject.MESHPeritoneal Neoplasms-
dc.subject.MESHPolyethylene Glycols-
dc.subject.MESHProgression-Free Survival-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.titleReal world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study-
dc.typeArticle-
dc.identifier.pmid31912673-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044005-
dc.subject.keywordOvarian Cancer-
dc.subject.keywordRecurrence-
dc.subject.keywordPlatinum-
dc.subject.keywordPrognosis-
dc.subject.keywordChemotherapy-
dc.contributor.affiliatedAuthorChang, SJ-
dc.type.localJournal Papers-
dc.identifier.doi10.3802/jgo.2020.31.e15-
dc.citation.titleJournal of gynecologic oncology-
dc.citation.volume31-
dc.citation.number2-
dc.citation.date2020-
dc.citation.startPagee15-
dc.citation.endPagee15-
dc.identifier.bibliographicCitationJournal of gynecologic oncology, 31(2). : e15-e15, 2020-
dc.identifier.eissn2005-0399-
dc.relation.journalidJ020050380-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:
31912673.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse